Crescendo Biologics has appointed Eva-Lotta Allan as non-executive director of the company with immediate effect. Eva-Lotta has over 30 years’ experience in the biopharmaceutical industry, most recently as chief business officer at clinical-stage T-cell receptor company, Immunocore. During her five years at Immunocore she raised $320 million in a Series A round, established significant strategic partnerships with top pharmaceutical companies and was elected to the Board of the BIA. She has also served on a number of other Boards in both private and publicly held companies during her career, and is currently a non-executive director for Targovax ASA.
